Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PainChek Ltd ( (AU:PCK) ) has provided an update.
PainChek Ltd has announced the cessation of 1,150,000 options, designated as PCKAR, which expired unexercised on 1 March 2026. The lapse of these options slightly reduces the potential future dilution of existing shareholders but does not immediately alter the company’s current issued capital or operating activities, suggesting a routine capital management event rather than a strategic shift.
The notification, lodged as an Appendix 3H with the ASX, formalises the removal of these expired securities from PainChek’s capital structure. This administrative update clarifies the company’s outstanding securities profile for investors and may marginally simplify future capital planning and reporting obligations.
More about PainChek Ltd
PainChek Ltd is an Australian-listed company in the healthcare technology sector, trading on the ASX under the code PCK. The company develops and commercialises digital tools, including its core PainChek product, which is designed to assess and manage pain, particularly in clinical and aged care settings.
Average Trading Volume: 162,761
Technical Sentiment Signal: Sell
Current Market Cap: A$31.35M
Find detailed analytics on PCK stock on TipRanks’ Stock Analysis page.